Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
about
Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.Can protein science solve the unmet needs in pancreatic cancer diagnosis and therapy?Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer.Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality?New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review
P2860
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@ast
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@en
type
label
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@ast
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@en
prefLabel
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@ast
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@en
P2093
P2860
P921
P356
P1476
Immunohistochemical hENT1 expr ...... emcitabine-based chemotherapy.
@en
P2093
N Kitteringham
N T E Bird
W Greenhalf
P2860
P304
P356
10.1002/BJS.10482
P407
P577
2017-03-01T00:00:00Z